Summary of Phase 3 INTRIGUE Trial Published
This summary article helps explain the results of Deciphera's Phase 3 INTRIGUE trial as published in Future Medicine, authored by Marina Symcox & Robin L Jones.
Examining Kidney Toxicities of Sunitinib and Imatinib in Long-Term GIST Therapy
On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]
Clinical Registry Study Planned by ASCO
American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR). ASCO plans should increase patient access to off-label drugs and match patients with [...]
Pfizer Releases New Dosage for Sutent Patients
Sutent 37.5 mg Ease of use and lower costs may be on the horizon for Sutent patients who are currently on a 37.5 milligram prescription. Available now, Pfizer has released a new [...]
Pregnancy Outcomes in Patients with CML Treated with Imatinib
Is pregnancy for me?, is a common question among GIST patients. At present there isn't a lot of data on pregnancy and GIST. The prescription information on Gleevec clearly warns of risks if a [...]
Our Decision to Enter Hospice
I’ve been thinking a lot about writing this article. The last thing I want to do is cause worry or pain to anyone reading this. Then I thought of all the people who could possibly benefit in the future from knowing ahead of time what we didn’t know at the time we needed to know it.
Sutent – What to Expect When You Begin
Sutent is the second-line approved treatment for Gastrointestinal Stromal Tumor and is prescribed when treatment with the first-line drug, Gleevec (Imatinib) is no longer effective or cannot be tolerated. The two drugs work differently, so [...]
Sutent Treatment Use Trial Results
Patients with GIST who received sunitinib using a flexible dose approach to manage adverse events remained on treatment longer than those who received the strict dose/schedule and exhibited better clinical outcomes (longer time to tumor progression and longer overall survival).